Nec corporation (20240161871). METHOD AND SYSTEM FOR OPTIMAL VACCINE DESIGN simplified abstract
Contents
- 1 METHOD AND SYSTEM FOR OPTIMAL VACCINE DESIGN
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 METHOD AND SYSTEM FOR OPTIMAL VACCINE DESIGN - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Original Abstract Submitted
METHOD AND SYSTEM FOR OPTIMAL VACCINE DESIGN
Organization Name
Inventor(s)
Brandon Malone of Heidelberg (DE)
METHOD AND SYSTEM FOR OPTIMAL VACCINE DESIGN - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240161871 titled 'METHOD AND SYSTEM FOR OPTIMAL VACCINE DESIGN
Simplified Explanation
The computer-implemented method described in the abstract involves selecting amino acid sequences for inclusion in a vaccine based on their ability to elicit an immune response. Here are some key points to explain the innovation:
- Identification of immune profile response values for candidate amino acid sequences.
- Retrieval and generation of representative immune profiles for a population.
- Selection of amino acid sequences for the vaccine that minimize the likelihood of no immune response for each representative immune profile.
Potential Applications
This technology could be applied in the development of vaccines for various diseases by optimizing the selection of immunogenic amino acid sequences.
Problems Solved
This technology addresses the challenge of identifying the most effective amino acid sequences for inclusion in a vaccine to elicit an immune response.
Benefits
The benefits of this technology include potentially improving the efficacy of vaccines by selecting the most immunogenic amino acid sequences for inclusion.
Potential Commercial Applications
A potential commercial application of this technology could be in the biopharmaceutical industry for the development of novel vaccines with enhanced immune response capabilities.
Possible Prior Art
One possible prior art in this field could be the use of computational algorithms to predict immunogenic epitopes for vaccine development.
What is the impact of this technology on vaccine development?
This technology could revolutionize vaccine development by enabling the selection of the most effective amino acid sequences to elicit an immune response, potentially leading to the development of more efficacious vaccines.
How does this method compare to traditional vaccine development approaches?
This method offers a more targeted and efficient approach to vaccine development by leveraging immune profile response values to select the most immunogenic amino acid sequences, potentially improving vaccine efficacy.
Original Abstract Submitted
a computer-implemented method of selecting one or more amino acid sequences for inclusion in a vaccine from a set of predicted immunogenic candidate amino acid sequences includes identifying an immune profile response value for each candidate amino acid sequence with respect to each one of a plurality of sample components of an immune profile. the immune profile response value represents whether the respective candidate amino acid sequence results in an immune response for the sample components of the immune profile. a plurality of immune profiles are retrieved for a population. a plurality of representative immune profiles are generated for the population. the representative immune profiles overlap with the sample components of the immune profiles. the one or more amino acid sequences for inclusion in the vaccine that minimises a likelihood of no immune response for each representative immune profile, based on the immune profile response values, are selected.
